

Innovative Approaches to Study Planning and Design: Power, Simulation and Adaptation

Bryan Luce, PhD, MS, MBA

Chief Science Officer, Office of the Chief Science Officer, Executive Team

Roger Lewis, MD, PhD

Professor, David Geffen School of Medicine at UCLA and Chair of the Department of Emergency Medicine at Harbor-UCLA Medical Center and Berry Consultants, LLC

September 21, 2015



Welcome!



Bryan Luce, PhD, MS, MBA
Chief Science Officer, Office of
the Chief Science Officer,
Executive Team



Roger Lewis, MD, PhD
Professor, David Geffen School of
Medicine at UCLA and Chair of the
Department of Emergency Medicine at
Harbor-UCLA Medical Center and
Berry Consultants, LLC

Innovative Approaches to Study Planning and Design: Power, Simulation and Adaptation

- Introduction (Bryan Luce)
 - Background
 - PCORI considerations
 - Concept
- Technical presentation (Roger Lewis)
 - Trial Design trial design simulation
 - Adaptive designs



Background

- Pragmatic Clinical Studies (PCS) may themselves be unfamiliar to applicants.
- PCSs are often complex in that they...
 - Study real world applications of interventions.
 - Address “what works for whom under what circumstances?” which may mean....
 - Multiple choices (thus, multiple arms may be appropriate)
 - Practice patterns and new innovations may change during the trial
 - May be complex and difficult to calculate power reliably
- Applicants may be unfamiliar with certain innovative trial design features, e.g. trial design simulation; Adaptive techniques. However...
- These (or other) innovative designs may be appropriate to consider



Thus, PCORI is Considering to...

- Encourage applicants to propose innovative design approaches (as appropriate)
- Recruit a cadre of experts in specialized trial design issues (e.g. design simulation, adaptive designs)
- Evaluate high scoring applications (prior to funding) for possible trial design consultation
- For selected applications, offer (at no cost to applicant) expert design consultation and possibly additional funding and time with aim to improve:
 - Power analysis
 - Trial flexibility (e.g. multiple arms, adaptation)
 - Trial efficiency
 - Scientific rigor



Questions?

- We will now have an in-depth discussion, during which you can provide feedback.
- Roger Lewis will then drill down into the science of these trial design issues.



Thank You!

Bryan Luce, PhD, MS, MBA

Chief Science Officer, Office of the Chief Science Officer, Executive Team

Roger Lewis, MD, PhD

Professor, David Geffen School of Medicine at UCLA and Chair of the
Department of Emergency Medicine at Harbor-UCLA Medical Center and
Berry Consultants, LLC



PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE